GET THE APP

A Short Note on Ledipasvir Sofosbuvir

Journal of Liver: Disease & Transplantation.ISSN: 2325-9612

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A Short Note on Ledipasvir Sofosbuvir

Ledipasvir sold below the brand Harvoni among others, may be a medication accustomed treat viral hepatitis. It's a fixeddose combination of ledipasvir and sofosbuvir. Cure rates are ninety four to ninety nine in individuals infected with viral hepatitis virus (HCV) genotype one. Some proof additionally supports use in HCV genotype three and four. It’s taken daily orally for 8–24 weeks. It is usually well tolerated. Common aspect effects embrace muscle pains, headache, nausea, rash, and cough. It is unclear if use in physiological state is safe for the baby. Ledipasvir works by decreasing the activity of NS5A and sofosbuvir works by decreasing the activity of NS5B enzyme.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

Associations